Werewolf Therapeutics (HOWL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Reni Benjamin from JMP Securities reiterated a Buy rating on the stock and has a $4.00 price target.
Reni Benjamin’s rating is based on several compelling factors that highlight Werewolf Therapeutics as a promising investment. The company has a strong cash position of $111 million, which is expected to sustain operations until the second quarter of 2026. This financial stability, coupled with a strategic partnership with Jazz Pharmaceuticals, enhances its growth prospects.
Furthermore, Werewolf is advancing its clinical pipeline with significant milestones on the horizon. The anticipated data from the WTX-124 expansion in the fourth quarter of 2025, along with ongoing discussions with the FDA for potential accelerated approval, underscore the company’s innovative approach. Additionally, the initiation of the WTX-330 Phase 1/2 study and the development of preclinical candidates targeting inflammatory diseases further bolster its long-term potential.
In another report released yesterday, Wedbush also reiterated a Buy rating on the stock with a $8.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com